<DOC>
	<DOCNO>NCT00373061</DOCNO>
	<brief_summary>The Xolair Pregnancy Registry observational study establish Genentech obtain data pregnancy outcome woman expose Xolair . Women expose least one dose Xolair within 8 week prior conception time pregnancy follow completion pregnancy . The evaluation infant conduct birth 6-month interval infant 12 month old .</brief_summary>
	<brief_title>An Observational Study Use Safety Xolair During Pregnancy</brief_title>
	<detailed_description />
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Eligibility enrollment base Xolair exposure woman , whether inadvertent deliberate , relation pregnancy . Women expose least one dose Xolair within 8 week prior conception pregnancy may include registry .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Expect</keyword>
</DOC>